CommercialCoverageMedium impact
08.02.47a, linvoseltamab-gcpt (Lynozyfic™)
Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
Jan 1, 2026
We identified it
Jun 19, 2026
Summary
A new commercial policy for linvoseltamab-gcpt (Lynozyfic™) has been updated and will take effect January 1, 2026. This appears to be a pharmacy policy related to a newly approved medication that may require specific billing procedures or coverage criteria.
Action Required
Before January 1, 2026: Billing team should review the full policy details at the provided URL to understand specific coverage criteria, prior authorization requirements, and billing procedures for linvoseltamab-gcpt (Lynozyfic™). Update billing systems and provider encounter forms as needed based on the complete policy requirements.